Perspectives for immunotherapy in endocrine cancer.

Abstract

The fight against cancer has seen major breakthroughs in recent years. More than a decade ago, tyrosine kinase inhibitors targeting constitutively activated signaling cascades within the tumor inaugurated a new era of oncological therapy. Recently, immunotherapy with immune checkpoint inhibitors has started to revolutionize the treatment of several malignancies, most notably malignant melanoma, leading to the renaissance and the long-awaited breakthrough of immunooncology. This review provides an overview of the basis of immunotherapy from its initial concepts of anti-tumor immunity and cell-based therapy to the development of immune checkpoint inhibitors and discusses published studies and the perspectives of immunooncology for the treatment of endocrine malignancies.

• Authors: S Latteyer, V Tiedje, B Schilling, D Führer
• Journal: Endocrine-related cancer (Endocr Relat Cancer) Vol. 23 Issue 10 Pg. R469-84 (10 2016) ISSN: 1479-6821 [Electronic] England
• PMID: 27485460 (Publication Type: Journal Article, Review)
• Copyright: © 2016 Society for Endocrinology.

Chemical References

• Antibodies, Monoclonal
• Protein Kinase Inhibitors

Topics

• Animals
• Antibodies, Monoclonal (therapeutic use)
• Cell Cycle Checkpoints (drug effects, immunology)
• Endocrine Gland Neoplasms (immunology, therapy)
• Humans
• Immunotherapy (methods, trends)
• Melanoma (drug therapy)
• Protein Kinase Inhibitors (therapeutic use)
• Skin Neoplasms (drug therapy)
• Melanoma, Cutaneous Malignant